Piece due to strong sales in Europe and Asia. [Non-English content] Life Sciences revenue by traditional segment, please see page 24. [Non-English content] Driven by price adjustment. [Non-English content] Cost-cutting measures, the impact of U.S. tariff refunds. [Non-English content] Here are the sales figures. [Non-English content] Revenue increased in all regions. [Non-English content] Sales increase in revenue due to higher sales. [Non-English content] Result: positive impact of foreign exchange rates. [Non-English content] Due to increased sales volume. [Non-English content] Due to growth in Diabetes Management in emerging markets and robust sales of diagnostics. [Non-English content] Adjustments made to operating income adjust to EBITDA. [Non-English content] Depreciation and price action. Total JPY 6.7 billion. [Non-English content] EBITDA to adjust to EBITDA: JPY 3.7 billion. Restructuring related expenses of JPY 370 million last year and JPY 140 million this year. [Non-English content] Including the assets and liabilities under consolidation. [Non-English content] The balance of goodwill was JPY 240 billion. [Non-English content] It increased by JPY 1.9 billion. [Non-English content] The figure decreased by JPY 5.2 billion. [Non-English content] Primarily due to rise in the market. [Non-English content] Decreased from 3.2 x. As a result of an increase of adjusted EBITDA. [Non-English content] Total JPY 14.3 billion. [Non-English content] Resulted in an outflow of JPY 3.3 billion. [Non-English content] Including capital expenditure. [Non-English content] Including capital expenditure. Resulted in an outflow of JPY 10 billion. [Non-English content] JPY 2.5 billion. [Non-English content] Thanks for your consideration. We intend to continue making steady progress in these areas. [Non-English content] Earnings forecast for the fiscal year ending March 2026. [Non-English content] Full year forecast, including our assumptions about. [Non-English content] We are significantly exceeded. [Non-English content] Such as the fact that the demand for equipment and [Non-English content] As well as the risk of rising prices. [Non-English content] The risks related to products such as service and PCs. [Non-English content] The yen has appreciated due to currency fluctuations. [Non-English content] The yen has declined. [Non-English content] After earning income. [Non-English content] The positive impact of exchange rates will diminish. [Non-English content] Which is the business environment. [Non-English content] Full year forecast for the time being. [Non-English content] Foreign exchange gains and losses. [Non-English content] Improvement on last year's loss of JPY 4.1 billion. [Non-English content] The position would result in a positive impact of JPY 0.4 billion. [Non-English content] A negative impact of JPY 40 million for the dollar. [Non-English content] Based on the sensitivity estimates. [Non-English content] Including at the current exchange rate. [Non-English content] That is all for the organization. This concludes my explanation. [Non-English content] Now we'd like to switch to Q&A session. Joining us as responder is Senior Executive Vice President, COO, CSO. [Non-English content] If you have questions. [Non-English content] Mr. Seiji Wakao, please. [Non-English content] Thank you, I'm Seiji Wakao of JPMorgan. [Non-English content] [Non-English content] Thank you. [Non-English content] We'll talk to the commission next week about the fiscal year forecast. [Non-English content] We'll put the agenda maintaining revisions and the higher-standard reasons. [Non-English content] When you have better visibility of variables. [Non-English content] The timing of potential revisions, can we consider it will be in the second quarter? [Non-English content] The forecast in the U.S., or the costs are also one of the variable factors, we understand it. Looking at the progress of OP, I think currently the progress rate is 40% in the full year forecast. Usually considering this future, I think that on a net basis there will be revisions upward. Can we consider that way? Thank you. I'd like to answer to your question. In May we announced the full year forecast, and back then BGM is. [Non-English content] Expectation. We may potentially. [Non-English content] I think we need to. [Non-English content] We will closely monitor the situation. [Non-English content] We will look into the situation, verifying the situation, what's going on. [Non-English content] We have to make a decision. At this point in time. [Non-English content] We cannot make any promises. We are not making a great revision. In the first quarter, we had strong performance. [Non-English content] In the second quarter. [Non-English content] The major point is how. [Non-English content] We need to monitor and verify how the things will be moving on in the quarter two and beyond. Thank you very much. I understand it very well. My second question is that Diabetes Management performed very well. I have a question. In the first quarter, emerging markets performed very well. [Non-English content] If I look at my information in Excel, I also thought that performance in Europe was also good, and I couldn't really understand the [Non-English content] The emerging markets. [Non-English content] Could you give us more details about the actual of the first quarter? Of course, the momentum in the first quarter, whether or not it will continue in the second quarter. I think Diabetes Management is a big factor for you to look at overall performance. If there are any risks, please also let us know. Thank you for your question. Sato, would like to answer to your question. The first quarter performance was strong. [Non-English content] Including Europe and the U.S. [Non-English content] We could expand the market share. That's the first element. Regarding emerging markets, as Yamaguchi mentioned in Algeria. [Non-English content] Also in the Middle East, which shows a decline in the previous year. We see the recovery there. These are the contributions from the emerging markets. Also India, Australia, compared to the last year, they are growing. It's a mixed situation. Mainly we have been expanding market share in Europe and the U.S. That's the main contributor. What our promise for the second quarter and beyond, I believe that the first quarter momentum will be able to be more maintained, and we don't expect any major changes. Regarding the margin, I see progress. Restructuring, I think the future is quite favorable. From the second quarter and beyond, is there any risk factors showing any decline in the margin in Diabetes Management? [Non-English content] 7%. The year-on-year comparison of the first quarter results. About 70% is avoiding increase, but 30% is profitability improvement. That's effective. I believe that they will continue to contribute to the profitability of margin. Thank you. If I supplement a little, in the first quarter we had strong results. [Non-English content] The numbers. [Non-English content] It will be more gradual. [Non-English content] This time margin was 33%. It was very good as a first quarter. [Non-English content] Decline in those businesses. [Non-English content] Probably becoming more gradual. Thank you very much. Talking about the phasing. [Non-English content] The phasing. [Non-English content] It is difficult to identify how much. [Non-English content] Mainly in Western countries. [Non-English content] In the U.S. [Non-English content] That's producing results in this fiscal year. [Non-English content] Their inventories. Q1 the adjustments of shipments. They are coordinated. [Non-English content] Input level was not too high. The sales shipment was also— [Non-English content] How much? Not to say accurately, but that is overall situation. Understood. Thank you very much. [Non-English content] Thank you. [Non-English content] Tokyo Intelligence, Mr. Masao. The floor is yours. [Non-English content] Thank you, Tokai Tokyo Intelligence Laboratory. My name is Masao Yoshida. Thank you for the opportunity. [Non-English content] That BGM is. [Non-English content] That's a good section. [Non-English content] Equipment, profit margin. BGM [Non-English content] I'm talking about BGM. [Non-English content] That's part of the reason of the risk. [Non-English content] Profit margin does not change throughout a year. [Non-English content] That's what we are seeing right now. [Non-English content] What about the situation there? [Non-English content] Present some policies, but what about the latest situations? [Non-English content] [Non-English content] This is all I have to say. [Non-English content] Thank you. These were the questions that I wanted to ask. [Non-English content] Mr. Ryotaro Hayashi, please. [Non-English content] Morgan Stanley Securities. Can you hear me okay? [Non-English content] What are the different points that you saw there were some differences between your plan and the actual? [Non-English content] That's a good assumption. That has relatively big impact. [Non-English content] [Non-English content] [Non-English content] [Non-English content] Next, Yamaguchi Hidemaru, it's your turn. [Non-English content] This is Yamaguchi. Do you hear me? Yes. [Non-English content] I have two quick questions. [Non-English content] Are we going to be even stronger than last year? [Non-English content] [Non-English content]